A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

Schmid P.Sablin M.-P.Bergh J.Im S.-A.YEN-SHEN LUMart?nez N.Neven P.Lee K.S.Morales S.P?rez-Fidalgo J.A.Adamson D.Gon?alves A.Prat A.Jerusalem G.Schlieker L.Espadero R.-M.Bogenrieder T.Huang D.C.-L.Crown J.Cort?s J.2021-03-102021-03-1020211465-5411https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099469940&doi=10.1186%2fs13058-020-01382-8&partnerID=40&md5=ee3fb2633e422c9c5f7193c7012f9233https://scholars.lib.ntu.edu.tw/handle/123456789/551326[SDGs]SDG3A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancerjournal article10.1186/s13058-020-01382-8334513452-s2.0-85099469940